Sai Parenterals lifts Australian OTC supply book to ₹1,506 crore
In short
Sai Parenterals signed a fresh AU$30 million, three-year supply agreement in Australia. That takes its total contracted OTC supply commitments in the country to AU$232 million, or about ₹1,506 crore.
This matters because it expands the company’s overseas business. The report says Sai Parenterals wants to shift production in-house, but it does not say when that will happen or what the profit impact will be.
What the reporting says
Sai Parenterals secured a fresh AU$30 million, three-year supply agreement in Australia, taking its total contracted OTC supply commitments there to AU$232 million, or about ₹1,506 crore. The latest renewal follows a larger AU$202 million agreement signed in July, and the company plans to move production from third-party manufacturers to its own facilities. The reporting does not say when the new contract starts or how margins may change.
Why it matters
Sai Parenterals secured a new AU$30 million, three-year supply agreement in Australia, lifting its total contracted OTC supply commitments there to AU$232 million, or about ₹1,506 crore. The renewal follows a larger AU$202 million agreement signed in July. The company is also looking to shift production away from third-party manufacturers to its own facilities, but the reporting does not give timing or financial impact details.